Results 111 to 120 of about 3,822 (260)

First platelet transfusion refractoriness in a patient with acute myelocytic leukemia: A case report. [PDF]

World J Clin Cases, 2023
Tu SK, Fan HJ, Shi ZW, Li XL, Li M, Song K.   +5 more
europepmc   +1 more source

The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation [PDF]

, 1998
Radiation-induced pancytopenia proved to be a suitable model system in mice and rhesus monkeys for studying thrombopoietin (TPO) target cell range and efficacy.
Eaton, D.L., Fielder, P.J., Hartong, S.C.C. (Simone), Neelis, K.J. (Karen), Thomas, G.R. (Roger), Wagemaker, G. (Gerard), Wognum, A.W. (Albert)   +6 more
core   +1 more source

Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study

American Journal of Hematology, Volume 101, Issue 3, Page 628-632, March 2026.
Zhenbin Wei, Rongrong Liu, Lingling Shi, Qiaochuan Li, Lianjin Liu, Baoshi Zheng, Chunjie Qin, Hong Chen, Guyun Wang, Meiqing Wu, Gaohui Yang, Ruolin Li, Zhaoping Gan, Qi Zhou, Jing Fan, Xuemei Zhou, Yinghua Chen, Zhiyu Zeng, Zhongming Zhang, Yongrong Lai   +19 more
wiley   +1 more source

Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Stem cells offer multifaceted therapeutic approaches for inflammatory diseases, each exhibiting distinct therapeutic properties. Hematopoietic stem cells, primarily through hematopoietic stem cell transplantation (HSCT), can effectively remodel the immune environment, showing particular promise in treating genetically linked cases.
Chen Wu, Zhi‐Ping Jin, Shu‐Qiang Weng, Ji‐Min Zhu, Ling Dong   +4 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Distribution for platelet antibody in patients with immune-mediated platelet transfusion refractoriness

Hematology
Objectives: HLA Class I, HPA (Human platelet antigen), CD36 allo/isoantibodies, and platelet glycoprotein autoantibodies are the primary causes of immune-mediated platelet transfusion refractoriness (iPTR).
Bing Zhang, Kairong Ma, Xinyu Huang, Xiaozhen Hong, Ying Liu, Zhipan Wu, Xianguo Xu, Faming Zhu   +7 more
doaj   +1 more source

Variazione dei parametri di funzionalita piastrinica durante la conservazione di buffy-coat [PDF]

, 2016
Introduzione: In questi ultimi 10 anni i metodi per la raccolta, la lavorazione e la conservazione dei concentrati piastrinici si sono rapidamente evoluti mentre, di pari passo, si è ampliato il numero delle patologie che si giovano di tale trattamento ...
FORNACIARI, IRENE
core  

Can We Really Believe This Platelet Count?

American Journal of Hematology, Volume 101, Issue 3, Page 566-567, March 2026.
James Manning, Simona Deplano, Ketan Patel, Barbara J. Bain   +3 more
wiley   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source